Document is current
Any future updates will be listed below
-
Authors
Sowithayasakul, Panjarat
Beckhaus, Julia
Özyurt, Jale
Bison, Brigitte
Friedrich, Carsten
Müller, Hermann L. https://orcid.org/0000-0003-4929-9966
-
Funding
Funding for this research was provided by:
Deutsche Kinderkrebsstiftung (H.L.M., DKS2014.13)
Deutsche Forschungsgemeinschaft (DFG OE 280/2-1)
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 2 June 2025
First Online: 7 June 2025
Declarations
:
: H.L.M. has received reimbursement of participation fees for scientific meetings and continuing medical education events from the following companies: Ferring, Pfizer, Sandoz/Hexal, Novo Nordisk, IPSEN, Rhythm Pharmaceuticals and Merck Serono. He has also received reimbursement of travel expenses from Merck Serono, Rhythm Pharmaceuticals, and IPSEN and a lecture honoraria from Pfizer. B.B. has received reimbursement for continuing medical education from Merck Serono. The other authors declared no conflicts of interest.
: The study protocols of HIT-Endo, KRANIOPHARYNGEOM 2000/2007 were accepted by the Ethics Committee of the University of Würzburg, Würzburg, Germany (140/99; 94/06); the protocol of KRANIOPHARYNGEOM Registry 2019 and NBACCHI (“Neurobiological Basis of Behavioral Abnormalities in Childhood-Onset Craniopharyngioma Patients with Hypothalamic Involvement”) were accepted by the Ethical Committee of the Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany (2019-046; 2016-095). The studies were conducted in accordance with the Declaration of Helsinki.
: All custodians were informed of the study protocols and gave written informed consent.
: KRANIOPHARYNGEOM 2000: NCT00258453; KRANIOPHARYNGEOM 2007: NCT01272622; KRANIOPHARYNGEOM Registry 2019: NCT04158284.
